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ess: dozol@hotmail.comSummary Chronic obstructive pulmonary disease (COPD) is characterised by a
chronic inflammatory process in the large and small airways, as well as in the lung
parenchyma. Although the role of oral corticosteroids in the management of acute
exacerbations of COPD is well documented, its role in stable COPD is not clear. We
examined the anti-inflammatory effect of inhaled budesonide on the percentage of
neutrophils and on interleukin-8 (IL-8) levels in bronchoalveolar lavage (BAL) and
their correlation with spirometry and symptom scores. Twenty-six patients with
stable COPD were randomised, in a double-blinded, placebo-controlled trial with
either 800 mg of inhaled budesonide or placebo for a 6-month period.
The budesonide-treated subjects had significant reductions in IL-8 levels in the
BAL after therapy (mean7SEM, 1.5370.72 at baseline vs. 0.7070.48 ng/ml at 6
months, P ¼ 0:004) and a reduction in the mean percentages of neutrophils
(17.1672.67% vs. 13.2572.28% P ¼ 0:002). The improvement in sputum production
was of borderline (P ¼ 0:058) significance but there was no improvement in lung
function.
In stable patients with COPD, treatment with inhaled budesonide for a period of 6
months has a positive effect on markers of lung inflammation, as assessed by
reduction in percentage neutrophils and IL-8 concentration in BAL.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is
one of the leading causes of death of increasing
prevalence; it is expected to be the fourth leading
cause of death worldwide within the next 20
years.1 Despite the enormous burden of the disease
in health, economic and personal terms, there is
lack of specific targeted treatments for this
disease. Only smoking cessation and oxygen ther-
apy have been shown to alter the progression of the
disease.2
COPD is characterised by a persistent airflow
obstruction with reduction in the maximum
expiratory flow. The pathogenesis of COPD is
multifactorial, involving airway inflammation,
protease–anti-protease imbalance, oxidative stress
and recurrent infection. The inflammatory process,
which contributes to the airway narrowing of the
small airways, manifests as increased number of
inflammatory cells such as neutrophils and CD8+ T
lymphocytes3: these cells have been implicated in
the development and progression of COPD. Inter-
leukin-8 (IL-8), one of the mediators that have a
role in the pathogenesis of COPD, along with LTB4
and TNF-alpha, is a cytokine with potent neutrophil
chemotactic and activation properties.4
Both inhaled and oral corticosteroids have anti-
inflammatory effects, causing improvements in
symptoms and pulmonary function in the treatment
of asthma. Although the role of oral corticosteroids
in the management of exacerbations of COPD is
well-documented,5 the role of inhaled steroids in
stable COPD is not clear. A number of studies have
been performed examining the effects of inhaled
steroids variously upon measures of inflammation
and of lung function, with conflicting results. Of
those studies that investigated airway inflamma-
tion, we are only aware of two which evaluated
lavage specimens,6,7 the others using sputum
samples.8,9
The aim of this study is to see if airway
inflammation in COPD would be changed by a 6
months course of budesonide therapy, given at a
dose of 800 mg daily, and to further assess whether
these changes improved symptoms and lung func-
tion tests in these patients.Materials and methods
Patients
Twenty-six patients with a medical history and
clinical and radiological findings consistent withstable mild to moderate COPD, according to GOLD
classification (8), were included in the study. Eight
subjects, whose postbronchodilator FEV1 value was
greater or equal than 80% of the predicted, were
considered as mild COPD and 18 subjects whose
FEV1 value was in the range between 50% and 80%
of the predicted were considered as moderate (2a)
COPD. All subjects had a smoking history of at least
20 pack-years and they had all ceased smoking at
least 1 year prior to enrollment.
Inclusion criteria were: (1) FEV1/FVCo70% and
FEV1450% the predicted value, (2) reversibility
with inhaled-b2-agonists (400 mg salbutamol) of less
than 200ml or less than 12% of predicted FEV1, (3)
stable COPD defined as no acute exacerbation
within the preceding 3 months, (4) no history of
systemic disease or other pulmonary disease, (5) no
therapy with inhaled or systemic corticosteroids
within 3 months prior to entry into the study and (6)
no history of asthma or atopy.
All of the patients were on therapy with inhaled
salbutamol and ipratropium bromide. In nine
patients, sustained-released theophyline was also
being given.
Informed content was obtained from the patients
and this study was approved by the Ethics Commit-
tee of the Ege University, Izmir, Turkey.Study design
The study was a randomised, double-blinded and
placebo-controlled design. Subjects received treat-
ment with either budesonide 400 mg (Astra-Zeneca)
twice a day or placebo, delivered by dry powder
inhaler. Patients were randomised by a computer-
generated, blinded randomisation list. The treat-
ment group was randomly assigned and was
balanced at a ratio of 1:1. There was no seasonal
difference with regard to viral infections, as the
intervention started at the beginning of April and
ended in November for both groups.
Spirometric tests, BAL analysis with broncho-
scopy were ascertained on entry into the study and
after 6 months of treatment. The patients main-
tained weekly diary cards in which they noted any
changes in symptoms from their baseline condi-
tions. Dyspnoea was scored as ‘‘0’’ for no symp-
toms, ‘‘1’’ for one–two episodes of breathlessness
daily, ‘‘2’’ for three or more episodes and ‘‘3’’ for
breathless most of the time. Cough was scored as
‘‘0’’ for none, ‘‘1’’ for one–two episodes daily, ‘‘2’’
for three or more episodes or ‘‘3’’ for persistent
cough. Sputum production was ranked as ‘‘0’’ for
none, ‘‘1’’ production only on rising, ‘‘2’’ for
occasional sputum production and ‘‘3’’ for frequent
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for the symptoms, treatment compliance and side
effects. When patients noticed two of the following
symptoms—increase in dyspnoea, sputum puru-
lence, increased sputum volume, a cold or fever,
they telephoned a member of the clinician team
and were seen by a doctor within 24 h to detect the
exacerbations.
Spirometry
Pulmonary function tests were performed by the
standard method using a dry rolling-seal spirom-
eter. Three technically adequate maneuvers were
required and the best values for postbronchodila-
tion FVC and FEV1 was accepted.
Bronchoscopy
Trans-nasal fiberoptic bronchoscopy was performed
using an Olympus flexible fiberoptic bronchoscope,
following the guidelines of the National Institutes
of Health. Premedication included atropine
(0.5mg-IM) administered 30min before the proce-
dure, with local upper airways anaesthesia with
5ml of 2% Lidocaine. All bronchoscopies were
performed in the morning about 10:00 am to avoid
diurnal variations. To perform lavage, the broncho-
scope was wedged into the segmental bronchus of
the middle lobe and 100 cm3 of sterile warmed
saline solution was infused. Fluid was gently
aspirated immediately after the infusion had been
completed and was collected in a sterile container.
The fluid was immediately centrifuged at 500g for
10min. Supernatants were removed and frozen in
1ml sterile polystyrene tubes at 80 1C.
IL-8 count
IL-8 concentrations were determined by two-site
sandwich IL-8 specific enzyme-linked immunosor-
bent assay (ELISA-Chemikline). The concentration
of IL-8 in the samples was calculated by comparison
to the curve obtained with different concentrations
of standards included in each kit. Tests were done
twice for validation.
BAL cell counts
The cell pellet was washed with phosphate-
buffered saline solution. Cells were resuspended
in Hank’s balanced salt solution and counted using a
haemochromocytometer chamber. Cytocentrifuges
were stained by the May–Gru¨nwald Giemsa meth-
od. The differential cell counts of macrophages,lymphocytes, neutrophils and eosinophils were
made under light microscopy at  400 magnifica-
tion, counting approximately 300 cells. The cells
were counted by our pathologicst who was also
blinded. All cell data are expressed as percentages.
Statistical analysis
Parametric data are expressed as the mean7SEM.
Baseline comparability of the treatment and
placebo groups was assessed for age, sex, smoking
history and spirometry. Parametric data were
compared using Student’s t test. Nonparametric
data comparisons were made using Mann–Whitney
U test between the two groups. Comparisons
between baseline and end of treatment data from
treatment and placebo group were made using
Wilcoxon’s signed rank test (2-tailed). Correlations
between different parameters were tested with
Spearmans rank test. In each case, a P value of
o0.05 was considered significant.Results
Initially a total of 26 ambulatory patients with a
medical history and clinical and radiological find-
ings consistent with stable COPD were included in
the study. Three patients (two in the placebo
group, one in the budesonide-treated group) were
withdrawn from the study, as they suffered
exacerbation of their disease and required systemic
steroid therapy. One patient was excluded for
failure to take the medication consistently. The
results presented are an analysis of 22 subjects (12
budesonide-treated subjects and 10 placebo-trea-
ted subjects) who completed the study. The 6
months course of treatment with inhaled budeso-
nide was well tolerated, with no significant side
effects except for minor oral candidiasis in four
patients. All patients underwent the bronchoscopic
procedures without any complication (Table 1).
After the treatment period, the neutrophil
percentage was significantly decreased in the
budesonide-treated subjects. The mean neutrophil
percentage before and after the budesonide treat-
ment were 17.1672.67 vs. 13.2572.28%, respec-
tively (P ¼ 0:002) and the mean neutrophil
percentage before and after the placebo treatment
were 15.272.48 vs. 14.571.96, respectively
(P ¼ 0:495). The mean BAL concentrations of
IL-8 before and after the treatment period, in the
budesonide group were 1.5370.72 vs. 0.707
0.48 ng/ml, P ¼ 0:004, respectively and in placebo
group were 0.4970.22 vs. 0.4770.26 ng/ml,
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Table 2 Bronchoalveolar lavage cellularity and IL-8 level.
Budesonide-treated Placebo-treated
Before treatment After treatment Before treatment After treatment
Macrophages (%) 76.6673.0059 82.4272.28 76.771.97 79.471.78
P ¼ 0:003 P ¼ 0:090
Neutrophils (%) 17.166772.67 13.2572.28 15.272.48 14.571.962
P ¼ 0:002 P ¼ 0:495
Lymphocytes (%) 7.071.49 5.1770.93 8.371.61 7.371.282
P ¼ 0:031 P ¼ 0:389
IL-8 (ng/ml) 1.53370.72 0.70370.486 0.48870.22 0.46870.256
P ¼ 0:004 P ¼ 0:767
Values are expressed as mean7SEM.
Table 1 Demonstrates the randomization of the patients.
Budesonide-treated Placebo-treated P
Number (male/female) 12 (11/1) 10 (7/3) 0.20
Age (years) 64.9171.68 65.972.24 0.73
Smoking history pack-years 45.5876.16 44.476.37 0.9
Spirometry
FVC (ml) 25007151.7 18907199.69 0.02y
FEV1 (ml) 16087150.48 11807147.42 0.06
FEV1 (%predicted) 61.172.7 57.373.1 0.56
FEV1/FVC % 64.471.9 6272.0 0.43
Bronchoalveolaer lavage
IL-8 (ng/ml) 1.5370.72 0.48870.223 0.23
Neutrophils (%) 17.1672.67 15.2072.48 0.67
Values are expressed as mean7SEM.
Mann–Whitney U test.
ySignificant P value for FVC.
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sidered the difference of IL-8 level and differ-
ence of neutrophil percentage between the groups,
we also found that it was statistically significant.
The mean IL-8 difference for the placebo and
budesonide group, was respectively (mean7SEM),
0.0270.17, and 0.8370.29 (P: 0.037). The mean
neutrophil difference for the groups respec-
tively was (mean7SEM) 0.770.84, and 3.970.55
(P: 0.004).
One budesonide-treated patient had exception-
ally high levels of IL-8 (Fig. 1); so there was a
difference in baseline between the two groups of
patients but the difference was not statistically
significant. We found a decrease in IL-8 level in 11
patients in budesonide treated group, and we founda decrease in IL-8 level in four patients and an
increase in IL-8 level in five patients in placebo
group.
The budesonide-treated subjects demonstrated
no statistically significant changes in the FVC and
FEV1, nor did the placebo group (Table 3).
The amounts of BAL fluid recovered during the
bronchoscopy procedures that were performed
before and after treatment were similar and about
45% of the given saline solution was recovered. We
also did not observe any difference between the
groups.
There was statistically significant correlation
between IL-8 and neutrophil count at baseline
(for all 22 patients, r ¼ 0:44, P ¼ 0:041), the fall in
IL-8 in the budesonide-treated arm correlated well
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Figure 1 Changes in IL-8 between baseline and 6 months in the budesonide-treated and placebo arms of the study.
Table 3 Spirometric changes.
Budesonide-treated Placebo-treated
Before treatment After treatment Before treatment After treatment
FEV1 (ml) 1608.337150.48 1662.57185.77 11807147.42 11307147.61
P ¼ 0:84 P ¼ 0:16
FVC (ml) 25007151.75 25257191.93 18907199.69 17957217.61
P ¼ 0:84 P ¼ 0:19
Values are expressed as mean7SEM.
Correlation between neutrophils and IL-8
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Figure 2 Correlation between neutrophil percentage and
IL-8 level in bronchoalveoler lavage.
D. Ozol et al.1498with the fall in neutrophil count (r ¼ 0:75,
P ¼ 0:013) (Fig. 2). The fall in lymphocyte count
in the budesonide-treated arm did not correlate
with the fall in IL-8.Analysis of symptoms showed that there was no
significant change in cough or dyspnoea score
between baseline and 6 months in either budeso-
nide-treated or placebo groups. The budesonide-
treated group showed an improvement in sputum
production which just fell short of statistical
significance (improved in six patients, worse in
one, unchanged in five, P ¼ 0:058): the placebo
arm showed no significant change in sputum
production.Discussion
Our results suggest that treatment with inhaled
budesonide for a period of 6 months has a positive
effect on lung inflammation, as assessed by
percentage of neutrophils and IL-8 concentration
in bronchoalveolar lavage (BAL), but this therapy
failed to improve lung function or daily symptoms
in patients with stable COPD. Like previous studies,
we decided to document the effect of inhaled
corticosteroids on symptomatic and functional
parameters for 6 months, to allow time for the
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meters.
Our study has certain limitations. Randomisation
was not perfect; in particular, there was a
difference in mean IL-8 at baseline in the two
arms, although this difference was not statistically
significant. The higher mean IL-8 in the budesonide-
treated group is largely due to an exceptionally
high value in one patient (Fig. 1). The statistical
significance of the change in IL-8 is retained if
this one patient is excluded from the analysis.
There was also a statistically significant difference
in baseline FVC between the two groups. We
were not able to ascertain total cell counts in
the lavage specimens. The strengths of our study
were that it examined BAL, while most previous
studies have examined sputum.10,11 BAL should
give a better assessment of small airways and
alveolar inflammation. The only two previous
studies of BAL have been small (Balbi examined
only eight patients and Thompson 20 in the
treated arm,7,9). Ours was a double-blind, place-
bo-controlled study. In our study, both subjective
symptoms and objective lung function were deter-
mined.
Our study supported the previous findings of Balbi
et al.7 that steroids can reduce concentrations of
IL-8 in BAL. Llewellyn-Jones11 also showed a
reduction in chemotactic activity of sputum after
treatment with fluticasone. In contrast, both
Culpitt et al.12 and Keatings et al.13 did not show
any improvement across a range of inflammatory
markers, including IL-8, in sputum. We demon-
strated a significant reduction in neutrophil count
in the budesonide-treated arm. This confirms
previous results on BAL7 and sputum.9,10 The
correlation between the change in IL-8 and change
in neutrophil count, between baseline and 6
months in the budesonide-treated group, is con-
sistent with the role of IL-8 in recruiting neutrophils
and suggests that the reduced neutrophil count
induced by steroid therapy is mediated by a
reduction in IL-8, although it does not prove
causality.
Of the subjective symptoms assessed, cough,
dyspnoea and sputum production, we only found a
possible improvement in sputum production, falling
just short of statistical significance. Katsura and
Kida14 showed improvements in both cough and
sputum production in elderly patients. The ‘Inhaled
Steroids in Obstructive Lung Disease (ISOLDE)
Study’ showed a moderation of the annual rate of
deterioration of subjective symptoms as assessed
by the St. George’s Respiratory Questionnaire but
details of the effects on individual symptoms have
not been published.15We failed to demonstrate any improvement in
FVC or FEV1 after budesonide treatment. Results of
small studies have been mixed: both Bourbeau
et al.16 and Confalonieri et al.9 have also failed to
show an improvement in FEV1, while Thompson
et al.6 and Wiener et al.17 both showed improve-
ments. Two studies, larger than ours, showed small
but significant improvements in FEV1 over 6
months.18,19 However, three studies, each sus-
tained for a period of 3 years (ISOLDE, European
Respiratory Society Study on COPD (EUROSCOP),
and Copenhagen City Lung Study), failed to show a
significant amelioration in the temporal decline in
FEV1
14,20,21 over this longer period. Lack of an
improvement in our, and other studies, may be due
to sub-optimal dosing; it has been suggested on the
basis of a meta-analysis that budesonide is required
at a dose of 1.6mg for an optimum effect.22Conclusion
Our study supports the published data showing
decrease in the inflammatory markers in BAL in
stable COPD patients using long-term inhaled
steroids, an improvement in sputum production of
borderline significance but fails to show any
improvement in cough, dyspnea or pulmonary
function. The decision, therefore, to use inhaled
corticosteroids in these patients is therefore still a
matter of clinical debate with assessment of both
objective and subjective parameters.Acknowledgments
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